Sanofi Genzyme reaffirms its commitment to support patients with rare diseases in India

• 20 years of providing free treatment to patients with rare disorders in India
• Partners with patient groups to raise awareness about rare diseases in India

Bengaluru, February 27, 2018: Sanofi Genzyme, the specialty care global business unit of Sanofi, reaffirms its commitment to go the extra mile for patients with rare diseases in India. It has partnered with patient support groups in major cities across the country on the occasion of Rare Disease Day (that falls on 28 February 2018) to raise awareness and sensitize the public about rare diseases in India.

Rajaram, Managing Director, Sanofi India, said,“Given the lowburden of rare diseases in the country, these patients are often ‘invisible’ to the public health system. They incur very high diagnostic and treatment costs and do not receive the guidance and support they need. Sanofi Genzyme is committed to working with the community of patients, physicians and researchers to enable effective diagnosis, focused education and sustainable access to treatment.”

Sanofi Genzyme is recognized as one of the industry’s most generous in-kind givers, and 2018 marks the 20^th year of Sanofi Genzyme’s humanitarian program in India. Through the charitable access program, known as INCAP (INdia Charitable Access Program), Sanofi Genzyme is currently providing free Enzyme Replacement Therapy to patients with Lysosomal Storage Disorders (LSDs) in India.

INCAP has grown significantly since its inception in 1999 and is widely appreciated for its altruistic efforts to support the LSD community by providing therapy to patients who lack sufficient financial resources to avail of these therapies. Today, over a hundred patients are benefitting from the enzyme replacement therapies being provided under INCAP, for rare diseases like Gaucher disease, Pompe disease, Fabry disease, and MPS I(Mucopolysaccharidoses) disease.

Sanofi Genzyme in India is focused on treatment for rare diseases, multiple sclerosis and immunology.

Corporate Comm India(CCI Newswire)